Drug Profile


Alternative Names: PXT-2331; PXT002331

Latest Information Update: 18 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Domain Therapeutics
  • Developer Prexton Therapeutics
  • Class Antiparkinsonians; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 4 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 06 Nov 2017 Prexton Therapeutics plans the phase II ATTUNED trial in Parkinson's disease (PXT-CL17-003; NCT03331848)
  • 04 Jul 2017 Phase-II clinical trials in Parkinson's disease (Treatment-experienced) in Austria, Germany (PO) (NCT03162874)
  • 02 Jun 2017 PXT 002331 is now called Foliglurax (NCT03162874)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top